Beximco Pharmaceuticals Ltd.

5th May 2009

Beximco Pharma launches 3 new Respirator solutions

More than 7 million people are suffering from asthma and COPD in Bangladesh and the number is increasing day by day. Considering the fact Beximco Pharmaceuticals Ltd. (BPL), the leading-edge pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh has recently introduced 3 new respirator solutions for the effective treatment of Asthma and COPD.

They are Azmasol® Respirator Solution, Iprasol® Respirator Solution, Ipramid® Respirator Solution.

Azmasol® Respirator Solution (Salbutamol 5 mg/ml is an aqueous solution of Salbutamol Sulphate BP). Azmasol® Respirator Solution is indicated for the treatment of severe acute asthma.

Azmasol® Respirator Solution is available in 20 ml glass bottle. Each ml of solution contains Salbutamol (as Salbutamol Sulphate BP) 5 mg. Ipramid® Respirator Solution (Ipratropium Bromide 250 mcg/ml) is an anticholinergic bronchodilator. Ipratropium bromide Respirator Solution may be used alone or in combination with other bronchodilators. Ipratropium bromide Respirator Solution when used in conjunction with Salbutamol is indicated for acute asthmatic attacks. Ipratropium bromide Respirator Solution is also indicated for the treatment of acute exacerbations of COPD.
Ipramid® Respirator Solution is available in 20 ml glass bottle. Each ml of solution contains Ipratropium Bromide 250 mcg.

Iprasol® Respirator Solution (Ipratropium Bromide 0.5 mg and Salbutamol 2.5 mg/ml). It is a combination of the anticholinergic bronchodilator, ipratropium bromide, and the ß2-adrenergic bronchodilator, salbutamol sulfate. For the management of COPD (chronic obstructive pulmonary disease).

Iprasol® Respirator Solution is available in 20 ml glass bottle. Each ml of solution contains Ipratropium Bromide BP 0.5 mg and Salbutamol (as Salbutamol Sulphate BP) 2.5 mg.